Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer

Indian Journal of Urology

Volumn 24, Issue 1, 2008, Pages 77-83

  Agarwal, Piyush K ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Cystectomy; Intravesical therapy; Nonmuscle invasive; T1G3; Transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

EID: 38349085269     PISSN: 09701591     EISSN: None     Source Type: Journal    
DOI: 10.4103/0970-1591.35760     Document Type: Article

References (58)

1. Globocan. 2002. Available from: http://www.dep.iarc.fr. [Last accessed on 2007 Jan 2].
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J din 2006;56:106-30.
3. Lee R Droller MJ. The natural history of bladder cancer: Implications for therapy. Urol din North Am 2000;27:1-13.
4. Heney NM, Ahmed S, Flanagan MJ, Frable W, Oorder MP, Hafermann MD, et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-6.
5. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-6.
6. Skinner DG. Management of invasive bladder cancer: Ameticulous pelvic lymph node dissection can make a difference. J Urol 1982;128:34-6.
7. Persad R Kabala J, Gillatt D, Penry B, Gingell JC, Smith PJ, Magnetic resonance imaging in the staging of bladder cancer. Br J Urol 1993;71:566-73.
8. Jakse G, Loidl W, SeeberG, Hofstadter E Stage T1, grade 3 transitional cell carcinoma of the bladder: An. unfavorable tumor? J Urol 1987;137:39-43.
9. Lamm DL Thor DE, Harris SC, Reyna JA Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980;124:38-40.
10. Sylvester RJ, van der MA Lamm DL Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
11. Hurle R, Losa A Manzetti A, Lembo A Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: A7-year follow-up. Urology 1999;54:258-63.
12. lamm DL, Blumenstein BA Crissman JD, Montie JF, Gottesman JF, Lowe BA et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional, cell carcinoma of the bladder: Arandomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
13. Pansadoro V, Emiliozzi P, de Paula E Scarpone R Pansadoro A Sternberg CN. Long-term follow-up of G3T1 transitional, cell carcinoma of the bladder treated with, intravesical bacilli Calmette-Guerin: 18-year experience. Urology 2002;59:227-31.
14. Sylvester RT, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis I, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
15. Patard J, Moudouni S, Saint E Rioux-Leclercq N, Manunta A Guy L et al. Tumor progression and survival in patients with T1C3 bladder tumors: Multicentric retrospective study comparing 94 patients treated during
16. years. Urology 2001;58:551-6.
17. Metwalli AR Kainat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 2006;6:1283-94.
18. Bohle A Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-7.
19. Sylvester RJ, Oosterlinck W van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
20. Bono AY Lovisolo JA Saredi G. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 2000;37:478-83.
21. van der Meijden AR Sylvester RI, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumours is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34.
22. Martinez-Pineiro JA Martinez-Pineiro I, Solsona E, Rodriguez RH, Gomez JM, Martin MG, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242-7.
23. Shahin O, Thalmann GN, Rentseh C, Mazzucchelli L Studer UE A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancers: Recurrence, progression and survival. J Urol 2003;169:96-100.
24. Chang SS, Cookson MS. Radical, cystectomy for bladder cancer: the case for early intervention. Urol din North Am 2005;32:147-55.
25. Cheng L Weaver AL Leibovich BC, Ramnani DM, Neumann SM, Scherer BG, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000;88:2326-32.
26. Lamm DL van der Meijden MR Morales A Brosman SA Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
27. Mack D, Frick J. Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. Br J Urol 1996;78:369-71.
28. Stein JE Indications for early cystectomy. Urology 2003;62:591-5.
29. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ, 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1999;161:1124-7.
30. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 2000;163:761-7.
31. O'Donnell MA Lilli K, Leopold C; National Bacillus CalmetteGuerin/ interferon phase 2 investigator group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-93.
32. Witjes JA Management of BCG failures in superficial bladder cancer: A review. Eur Urol 2006;49:790-7.
33. Ghoneim MA el-Mekresh MM, el-Baz MA el-Attar IA, Ashamallah A Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol 1997;158:393-9.
34. Masood S, Sriprasad S, Palmer JH, Mufti. GR T1G3 bladder cancer -indications for early cystectomy. Int Urol Nephrol 2004;36:41-4.
35. Soloway MS, Lopez AE, Patel J, Lu Y Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994;73:1926-31.
36. Freeman JA Esrig D, Stein JR Simoneau AR Skinner EC, Chen SC, et al. Radical cystectomy for high risk patients with superficial, bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9.
37. Cookson MS, Herr HW, Zhang ZR Soloway S, Sogani PC, Fair WR The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
38. Stockle M, Aken R Engelinann U, Jacobi GH, Riedmiller H, Hohenfellner R Radical cystectomy - often too late? Eur Urol 1987;13:361-7.
39. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial, bladder tumors? J Urol 2001;166:1296-9.
40. Stein .IR Lieskovsky G, Cote R Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
41. Sanchez-Ortiz RF, Huang WC, Mick R Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110-5.
42. Henningsohn L Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002;168:168-75.
43. Hart S, Skinner EC, Meyerowitz BE, Boyd S, lieskovsky G, Skinner DG. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999;162:77-81.
44. Schoenberg MR Walsh PC, Breazeale DR Marshall FR Mostwin JI, Brendler CB. Local recurrence and survival following nerve sparing radical- cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996;155:490-4.
45. Chatterjee SJ, Datar R Yiussefzadeh D, George B, Goebell PJ, Stein JR et al. Combined effects of p53, p21 and pRb expression in the progression of bladder transitional cell carcinoma. Jdin Oncol 2004;22:1007-13.
46. Esrig D, Hmajian D, Groshen S, Freeman JA Stein JR Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
47. Pfister Q Hainan JM, Dunet E Grise R Frebourg T p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 1999;162:69-73.
48. Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez R Barre P, et al. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1C3 bladder cancer. J Urol 1998;159:788-91.
49. Peyromaure M, Weibing S, Sebe R Verpillat P, Toublanc M, Dauge MC, et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 2002;59:409-13.
50. Mellon K, Wright C, Kelly P, Home CH, Neal DE long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919-25.
51. Lopez-Beltran A Luque RJ, Avarez-Kndelan J, Quintero A Merlo F, Carrasco JC, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21 Waf1, p27kip1, cyclin D1 and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606-12.
52. Griffiths TR, Charlton M, Neal DE Powell PH Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002;167:2408-12.
53. Solsona E Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with, high risk superficial bladder cancer. J Urol 2000;164:685-9.
54. Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994;43:782-6.
55. Orsola A Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-8.
56. Riley GR Potosky AL Luhitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-41.
57. Botteman MF, Pashos CL, Redaelli A Laskin B, Hauser R, The health economics ofbladder cancer: Acomprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
58. Indurkhya A Mitra N, Schrag D. Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med 2006;25:1561-76.